Stockscreener 앱 받기
0.00
100.00%
-8.16
시간 외 거래:
8.02
8.02
+
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
0.68%
0.50%
자본화:
|
볼륨(24시간):